Hoth Therapeutics (HOTH) said Thursday that it entered into an exclusive patent license agreement with the US Department of Veterans Affairs to develop obesity treatment.
The deal also gives Hoth the rights to a patent co-developed by the department and Emory University, the company said.
Financial details weren't provided.
The technology uses the Glial Cell Line-Derived Neurotrophic Factor to treat obesity and related health conditions. The agreement includes a detailed development plan to guide the technology from research to commercialization, with the goal of making it widely accessible, the company said.
Shares of Hoth fell 6.3% in recent trading.
Price: 0.74, Change: -0.05, Percent Change: -6.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.